Ruxolitinib, an inhibitor of Janus kinase (JAK) 1 and 2, has been approved for the treatment of myelofibrosis (MF) and polycythemia vera (PV) by reducing spleen size, ameliorating debilitating symptoms, and improving overall survival.[1,2] The JAK/signal transducer and activator of transcription (STAT) pathway is the principal signaling mechanism for numerous cytokines and growth factors. The gene discussed is SOAT1; the disease is acquired polycythemia vera.